Market Research Reports, Inc.

Asia-Pacific Colorectal Cancer Therapeutics Market Is Expected to Reach $2.9 Billion by 2020; Find New Report

Market Research Reports, Inc. has announced the addition of “Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2020 - Improved Regional Healthcare Access to Drive Uptake of High-Cost Targeted Therapies” research report to their offering.


Lewes, DE -- (SBWIRE) -- 11/17/2014 -- The Colorectal Cancer (CRC) therapeutics market in the four Asia-Pacific (APAC) countries of India, Australia, China and Japan was worth $1.9 billion in 2013 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 6.5% to $2.9 billion by 2020. Japan had the largest market in 2013, with a value of $1.2 billion, or a 65% share of the combined market of the four countries. It was followed by China, with $491m, or 26%; Australia, with $117m, or 6.2%; and India, which had the lowest market share and value, with 2.7% and $52m, respectively, but is expected to witness the fastest growth over the forecast period, with a CAGR of 11%. The respective CAGRs of China, Australia, and Japan during the forecast period are estimated to be 9%, 7.5%, and 5%.

The use of targeted therapies is expected to increase in the Asia-Pacific (APAC) markets (for the purposes of this report, APAC refers to Australia, China, India and Japan only), as patient access to these more expensive agents improves. The moderate uptake of late-stage pipeline products panitumumab and Xilonix, following their expected approval, is expected to drive additional growth within this market. Others such as ramucirumab, TAS-102, TS-1, MelCancerVac will also contribute. The total value of the CRC market will increase slightly over the forecast period, owing to the increased uptake of branded drugs, and the number of premium-priced agents, the gradual increase in the use of targeted therapies, and a rise in the incident population, will create growth in the market.

The CRC pipeline is highly robust, with potential drug candidates across various phases of clinical development. With nearly 400 active pipeline molecules, the majority of the investigational drug candidates are being evaluated for the treatment of CRC in advanced stages, either as first-line or second-line therapies. The current investigational pipeline candidates include new combination therapies and targeted therapies, as well as promising immunotherapies and chemotherapy drug candidates. As well as these active progressing pipeline molecules, the pipeline also includes nearly 180 molecules that are either inactive or discontinued.

As displayed in the following figure, from 392 active progressing pipeline molecules, 125 (32%) are in Phase II of development, 115 (29%) are in the Preclinical stage of development, 95 (24%) are in Phase I, and 10 (3%) are in Phase III. As well as these, a substantial number of active drug candidates are in the discovery stage. As shown in panel B, most of the pipeline drugs are novel, and a few are either generics or products that have already been marketed for other indications.

Know more about this report:

Find other ‘Therapeutic’ reports:

About Market Research Reports, Inc.
Market Research Reports, Inc. is the world's leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.

For regular industry updates subscribe to our newsletter at: